BioTuesdays

Category - Feature

Feature

In conversation with Todd Wyche

By Len Zehr As CEO and a co-founder of Brinson Patrick Securities, Todd Wyche has championed the use and growth of at-the-market offerings (ATMs) for the past 17 years for REITs, energy companies and most recently...

July 2, 2013
Feature

Avivagen shifts to commercial mindset from R&D

By Len Zehr Cameron Groome, who moved into the executive suite at Avivagen (TSX-V:VIV) in March, has transformed the focus of the animal wellness company to a business and product development engine and away from an...

June 18, 2013
Feature

Oramed readies oral insulin study in U.S.

By Len Zehr Oramed Pharmaceuticals (NASDAQ:ORMP) is awaiting a decision from the FDA, possibly later this week, to conduct a sub-study of the safety of its oral insulin candidate, ORMD-0801, before proceeding to a...

May 7, 2013
Feature

Vaxil trial validates vaccine technology

By Len Zehr Results of a recent clinical trial of Vaxil Bio’s (TASE:VAXL) ImMucin cancer vaccine in patients with multiple myeloma has validated the company’s VaxHit technology by demonstrating safety and a strong...

April 23, 2013
Feature

OnPoint’s Big-Data Equals Big Opportunity

By Len Zehr OnPoint Medical Diagnostics (OTCQB:ONMD) is pioneering a “big-data” platform for delivering measurable, objective and automated quality assurance (QA) solutions for magnetic resonance imaging (MRI), with...

April 16, 2013
Feature

DURECT awaiting Pfizer meeting with FDA on Remoxy

By Len Zehr DURECT (NASDAQ:DRRX) has a lot riding on a meeting in late March between its marketing partner, Pfizer, and the FDA to discuss resubmitting a new drug application for its lead pain drug, Remoxy, as a tamper...

February 26, 2013